Cystic fibrosis treatment clears the way


Stabilising a mucus attacking enzyme with cross-links could allow it to be delivered orally to fight infections in cystic fibrosis patients.

Pseudomonas aeruginosa is one of the commonest opportunistic pathogens in cystic fibrosis. The bacterium produces alginate, a polysaccharide which causes significant mucus build-up in the lungs and intestine. In addition to affecting patients’ quality of life, this also significantly obstructs the delivery of antibiotics, requiring increased dosages which can lead to antibiotic resistance and an increased chance of side-effects.

Guillermo Castro at the National University of La Plata in Argentina, and his team, investigate the delivery of drugs with significant administrative problems. They have turned their attention to the delivery of alginate lyase, an enzyme that degrades alginate and breaks-down mucus. ‘Our idea is to “dissolve” the mucus produced. The enzyme action facilitates antibacterial contact with the bacteria surface, and reduces the amount of antibiotic administered,’ explains Castro.

Cross-linking alginate lyase in the presence of BSA stabilises the enzyme but leaves the active site intact

However, as with most enzymes, alginate lyase is very sensitive to environmental factors such as salt, temperature and pH changes. These are significant barriers to administration, particularly oral administration. To address this problem the team have used a cross-linking enzyme aggregation (CLEA) approach where the alginate lyase was precipitated out of solution and cross-linked with glutaraldehyde. Through a systematic study, the team found that the inclusion of bovine serum albumin (BSA) and low methoxylated pectin boosted the activity of the immobilised enzyme, reducing the viscosity of an alginate solution by 25%, while leaving the alginate lyase CLEA stable enough for oral administration.

 

Rok Borštnar who researches designs for new drugs at the National Institute of Chemistry in Slovenia, says that the findings are significant. ‘Alginate lyase CLEA not only showed potential for the treatment of cystic fibrosis by oral delivery but also a potential and attractive biocatalyst for broader industrial purposes.’

The team will now investigate their approach for in vivo systems and look forward to working with cystic fibrosis and pharmaceutical institutions to bring their approach to the market.

References

This paper is free to access until 7th April 2014. Download it here:

G A Islan et al, RSC Adv., 2014, 4, 11758 (DOI: 10.1039/c3ra47850e)


Related Content

New cystic fibrosis drug in EU

31 July 2012 Business

news image

Ivacaftor works by helping defective proteins function more normally

Sodium alginate

17 September 2014 Podcast | Compounds

news image

When Brian Clegg's acid reflux strikes, he knows he can rely on help from this compound: Sodium alginate

Most Read

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

DNA 'barcodes' used to track food

30 October 2014 Research

news image

Milk has been successfully tracked as it is turned into cheese and yogurt in an advance that could fight food fraud

Most Commented

Square planar iron complex breaks inorganic dogma

31 October 2014 Research

news image

Unusual spin state could open the door to new and exciting chemistry

Indian U-turn on diabetes drug ban

16 August 2013 News and Analysis

news image

Suspension of cheap and popular medicine reversed but will now come with new safety warnings